Dianthus Therapeutics DNTH Cash Flow Statement
| FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|
| -$84.97M-95.1% | -$43.56M+25.1% | -$58.12M+18.3% | ||
| $96K-79.8% | $475K-67.5% | $1.46M-27.7% | ||
| $12.89M+345% | $2.9M— | —— | ||
| -$78.18M-112% | -$36.86M— | —— | ||
| $105K— | —— | $314K-75.2% | ||
| -$287.98M— | —— | -$59.82M— | ||
| $257.82M+86.2% | $138.44M+43.2% | $96.68M+7.9% | ||
| -$109.37M— | —— | —— | ||
| -$78.29M-112% | -$36.97M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Dianthus Therapeutics's cash flow data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.